Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study

J Am Acad Dermatol. 2019 Apr;80(4):1141-1143. doi: 10.1016/j.jaad.2018.10.006. Epub 2018 Oct 18.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Adalimumab / therapeutic use
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Dermatologic Agents / therapeutic use*
  • Drug Therapy, Combination
  • Etanercept / therapeutic use
  • Female
  • Humans
  • Infliximab / therapeutic use*
  • Male
  • Middle Aged
  • Pyoderma Gangrenosum / drug therapy*
  • Retrospective Studies
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Young Adult

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • golimumab
  • Infliximab
  • Adalimumab
  • Etanercept